Masitinib - Adjunct Therapy For Mild-To-Moderate Alzheimer's
May 20, 2026
AB Science is developing a promising adjunct drug for treating Alzheimer’s disease (AD). The drug is known as Masitinib. This is an oral tyrosine kinase inhibitor. The target patient for Masitnib are people with mild-to-moderate AD.
